US29251M1062 - Common Stock
ENANTA PHARMACEUTICALS INC
NASDAQ:ENTA (3/28/2024, 8:07:10 PM)
After market: 17.46 0 (0%)17.46
+0.93 (+5.63%)
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 145 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs, with an emphasis on treatments for viral infections. Its primary wholly owned research and development programs are in virology, namely respiratory syncytial virus (RSV), SARS-CoV-2, Hepatitis B virus (HBV) and Human metapneumovirus (hMPV). The firm has discovered glecaprevir, the second of two protease inhibitors discovered and developed for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is a co-formulated direct-acting antiviral (DAA), combination treatment for HCV, which is marketed under the tradenames MAVYRET and MAVIRET. Its lead clinical candidate for the treatment of chronic infection with HBV, is EDP-514. Its lead clinical candidate for COVID-19 is EDP-235. The firm's clinical stage program for RSV, with two compounds in clinical trials includes EDP-938 and EDP-323.
ENANTA PHARMACEUTICALS INC
500 Arsenal Street
Watertown MASSACHUSETTS 02472
P: 16176070800
CEO: Jay R. Luly
Employees: 145
Website: https://www.enanta.com/
Here you can normally see the latest stock twits on ENTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: